Fundraising Fox

Oragenics

NYSE: OGEN

Tampa, US · Florida corporation

oragenics.com ↗

Oragenics is a biotech company developing ONP-002, an intranasal neurosteroid drug delivered via a proprietary nasal device to treat the underlying brain injury in concussion patients. The therapy is in clinical development, with Phase 1 complete and Phase 2 trials underway, aiming to address inflammation, oxidative stress, and swelling from brain trauma.

BiotechLongevityMedical Devices

Founders & leadership

AJ
Alan JoslynExecutive
MS
Michael SullivanExecutive

Board

RK
Robert KoskiBoard director
FT
Frederick TellingBoard director
AD
Alan DuntonBoard director
CP
Charles PopeBoard director

Reported raises · per SEC filings

Form D private placements

$19.9M disclosed across 6 rounds · 2016–2023

▶$850KraisedAug 2023 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alan DuntonDirector
  • Frederick TellingDirector
  • Kimberly MurphyExecutive Officer, Director
  • Janet HuffmanExecutive Officer
  • Charles PopeDirector
  • Robert KoskiDirector
Offering amount
$850K
Amount sold
$850K
Minimum investment
$100K
First sale
Aug 2023
Incorporated
Corporation, Florida
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.6MraisedMay 2020 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Charles PopeDirector
  • Michael SullivanExecutive Officer
  • Robert KoskiDirector
  • Frederick TellingDirector
  • Alan JoslynExecutive Officer, Director
  • Alan DuntonDirector
Amount sold
$4.6M
First sale
May 2020
Incorporated
Corporation, Florida
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.8MraisedApr 2018 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alan JoslynExecutive Officer, Director
  • Frederick TellingDirector
  • Charles PopeDirector
  • Robert KoskiDirector
  • Alan DuntonDirector
  • Michael SullivanExecutive Officer
Offering amount
$1.8M
Amount sold
$1.8M
Sales commissions
$144K
Placement agents
LADENBURG THALMANN & CO. INC.
First sale
Apr 2018
Incorporated
Corporation, Florida
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.7MraisedNov 2017 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Charles PopeDirector
  • Michael SullivanExecutive Officer
  • Frederick TellingDirector
  • Robert KoskiDirector
  • Alan DuntonDirector
  • Alan JoslynExecutive Officer, Director
Offering amount
$6.7M
Amount sold
$6.7M
First sale
Nov 2017
Incorporated
Corporation, Florida
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedMay 2017 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert KoskiDirector
  • Frederick TellingDirector
  • Alan DuntonDirector
  • Charles PopeDirector
  • Michael SullivanExecutive Officer
  • Alan JoslynExecutive Officer, Director
Offering amount
$3M
Amount sold
$1.3M
First sale
May 2017
Incorporated
Corporation, Florida
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.7MraisedJul 2016 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Frederick TellingDirector
  • Alan DuntonDirector
  • Alan JoslynExecutive Officer, Director
  • Michael SullivanExecutive Officer
  • Robert KoskiDirector
  • Charles PopeDirector
Offering amount
$4.7M
Amount sold
$4.7M
First sale
Jun 2016
Incorporated
Corporation, Florida
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap
Robinhood46 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha30 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
Simply Wall St30 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.

Companies competing with Oragenics for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 6 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2021$256.7K
National Science FoundationPhase II2008$500K
National Institutes of Health (NIH)National Institutes of HealthPhase I2007$100K
National Science FoundationPhase I2006$99.3K
National Science FoundationPhase I2004$100K
National Institutes of Health (NIH)National Institutes of HealthPhase I2004$100K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Oragenics do?
Oragenics is a biotech company developing ONP-002, an intranasal neurosteroid drug delivered via a proprietary nasal device to treat the underlying brain injury in concussion patients. The therapy is in clinical development, with Phase 1 complete and Phase 2 trials underway, aiming to address inflammation, oxidative stress, and swelling from brain trauma.
How much funding has Oragenics raised?
Oragenics has disclosed $19.9M raised across 6 rounds.
Where is Oragenics headquartered?
Oragenics is headquartered in Tampa, US.